Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis

Inflammatory Bowel Diseases

Volumn 23, Issue 5, 2017, Pages 753-766

  Constante, Marco ^a,b   Fragoso, Gabriela ^b   Lupien Meilleur, Joseph ^b   Calvé, Annie ^b   Santos, Manuela M ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

iron; microbiota; probiotics

Indexed keywords

EDETIC ACID; FERROUS SULFATE; IRON; IRON GLYCINATE; PROBIOTIC AGENT; RNA 16S; STREPTOMYCIN; DEXTRAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDETES; CELL INFILTRATION; CLOSTRIDIALES; COLON FLORA; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIET SUPPLEMENTATION; DNA EXTRACTION; ESCHERICHIA COLI; FEMALE; HISTOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRON THERAPY; LACTOBACILLUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; ANIMAL; C57BL MOUSE; COLITIS; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE MODEL; INTESTINE ABSORPTION; MICROFLORA; PROTECTION;

ANIMALS; COLITIS; DEXTRAN SULFATE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; INTESTINAL ABSORPTION; IRON; MICE; MICE, INBRED C57BL; MICROBIOTA; PROBIOTICS; PROTECTIVE FACTORS;

EID: 85019871827     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001089     Document Type: Article

References (84)

1. Loréal O, Cavey T, Bardou-Jacquet E, et al. Iron, hepcidin and the metal connection. Front Pharmacol. 2014;5:128.
2. Andrews NC. Disorders of iron metabolism. New Engl J Med. 1999;341: 1986-1995.
3. Gozzelino R, Arosio P. Iron homeostasis in health and disease. Int J Mol Sci. 2016;17:130.
4. Kamada N, Chen GY, Inohara N, et al. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14:685-690.
5. Dostal A, Chassard C, Hilty FM, et al. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats. J Nutr. 2012;142:271-277.
6. Pereira DI, Aslam MF, Frazer DM, et al. Dietary iron depletion at weaning imprints low microbiome diversity and this is not recovered with oral Nano Fe (III). Microbiologyopen. 2015;4:12-27.
7. Guo X, Liu S, Wang Z, et al. Metagenomic profiles and antibiotic resistance genes in gut microbiota of mice exposed to arsenic and iron. Chemosphere. 2014;112:1-8.
8. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
9. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
10. Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2010;16:2034-2042.
11. Martinez C, Antolin M, Santos J, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103:643-648.
12. Martinez-Medina M, Aldeguer X, Lopez-Siles M, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis. 2009;15:872-882.
13. Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates speciesspecific antibody. J Gastroenterol Hepatol. 2002;17:849-853.
14. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
15. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol. 1997;150:91-97.
16. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145: 745-757.
17. Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123:700-711.
18. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. New Engl J Med. 1990;323:1228-1233.
19. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology. 2010;138:2101-2114.
20. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancerspecific mortality of colon adenocarcinoma. Clin Cancer Res. 2009;15: 5878-5887.
21. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-1523.
22. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med. 2004;116(suppl 7A):11S-26S.
23. Nielsen OH, Ainsworth M, Coskun M, et al. Management of irondeficiency anemia in inflammatory bowel disease: A systematic review. Medicine. 2015;94:e963.
24. Seril DN, Liao J, Ho KL, et al. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci. 2002;47:1266-1278.
25. Carrier J, Aghdassi E, Cullen J, et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002;132:3146-3150.
26. Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1-40.
27. Chua AC, Klopcic BR, Ho DS, et al. Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice. PLoS One. 2013;8:e78850.
28. Werner T, Wagner SJ, Martinez I, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut. 2011;60: 325-333.
29. Ettreiki C, Gadonna-Widehem P, Mangin I, et al. Juvenile ferric iron prevents microbiota dysbiosis and colitis in adult rodents. World J Gastroenterol. 2012;18:2619-2629.
30. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. [published online ahead of print February 4, 2016]. doi: 10. 1136/gutjnl-2015-309940.
31. Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731-742.
32. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: A randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr. 2010;92:1406-1415.
33. Dostal A, Lacroix C, Pham VT, et al. Iron supplementation promotes gut microbiota metabolic activity but not colitis markers in human gut microbiota-associated rats. Br J Nutr. 2014;111:2135-2145.
34. Jeppsen RB, Borzelleca JF. Safety evaluation of ferrous bisglycinate chelate. Food Chem Toxicol. 1999;37:723-731.
35. Heimbach J, Rieth S, Mohamedshah F, et al. Safety assessment of iron EDTA [sodium iron (Fe3+) ethylenediaminetetraacetic acid]: summary of toxicological, fortification and exposure data. Food Chem Toxicol. 2000; 38:99-111.
36. Wienk KJH, Marx JJM, Santos M, et al. Dietary ascorbic acid raises iron absorption in anaemic rats through enhancing mucosal iron uptake independent of iron solubility in the digesta. Br J Nutr. 1997;77:123-131.
37. Huang YL, Chassard C, Hausmann M, et al. Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice. Nat Commun. 2015;6:8141.
38. Layoun A, Santos MM. Bacterial cell wall constituents induce hepcidin expression in macrophages through MyD88 signaling. Inflammation. 2012;35:1500-1506.
39. Fillebeen C, Gkouvatsos K, Fragoso G, et al. Mice are poor heme absorbers and do not require intestinal Hmox1 for dietary heme iron assimilation. Haematologica. 2015;100:e334-e337.
40. Zhang J, Kobert K, Flouri T, et al. PEAR: A fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics. 2014;30:614-620.
41. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7: 335-336.
42. Jari Oksanen FGB, Kindt R, Legendre P, et al. Vegan: community ecology package. R package version 2. 3-2. Available at: http://CRAN. R-project. org/package1/4vegan. 2015. Accessed August 1, 2016.
43. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria. Available at: http://www. R-project. org/. 2015. Accessed August 1, 2016.
44. Cook JD, Reusser ME. Iron fortification: An update. Am J Clin Nutr. 1983; 38:648-659.
45. Ferrari P, Nicolini A, Manca ML, et al. Treatment of mild nonchemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomed Pharmacother. 2012;66:414-418.
46. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814-821.
47. Deriu E, Liu Janet Z, Pezeshki M, et al. Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe. 2013;14:26-37.
48. Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr Issues Intestinal Microbiol. 2006;7:73-89.
49. Balish E, Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol. 2002;160: 2253-2257.
50. Franz CM, Huch M, Abriouel H, et al. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol. 2011;151:125-140.
51. Tims S, Derom C, Jonkers DM, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J. 2013;7:707-717.
52. Faith JJ, Ahern PP, Ridaura VK, et al. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci Transl Med. 2014;6:220ra211.
53. Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17:1519-1528.
54. Kverka M, Zakostelska Z, Klimesova K, et al. Oral administration of parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 2011;163:250-259.
55. Dostal A, Lacroix C, Bircher L, et al. Iron modulates butyrate production by a child gut microbiota in vitro. MBio. 2015;6:e01453-e01415.
56. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap Am J Gastroenterol. 2011;106:1872-1879.
57. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671-1676.
58. Duncan SH, Holtrop G, Lobley GE, et al. Contribution of acetate to butyrate formation by human faecal bacteria. Br J Nutr. 2004;91: 915-923.
59. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79.
60. Zenewicz LA, Yin X, Wang G, et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol. 2013;190: 5306-5312.
61. Winterbourn CC. Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicol Lett. 1995;82-83:969-974.
62. Toblli JE, Cao G, Angerosa M. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats. Drug Des Devel Ther. 2015;9:2585-2597.
63. Kortman GA, Dutilh BE, Maathuis AJ, et al. Microbial metabolism shifts towards an adverse profile with supplementary iron in the TIM-2 in vitro model of the human colon. Front Microbiol. 2015;6:1481.
64. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12: 995-999.
65. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
66. Wreesmann CT. Reasons for raising the maximum acceptable daily intake of EDTA and the benefits for iron fortification of foods for children 6-24 months of age. Matern Child Nutr. 2014;10:481-495.
67. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519:92-96.
68. Carpenter BM, Whitmire JM, Merrell DS. This is not your mother's repressor: The complex role of fur in pathogenesis. Infect Immun. 2009; 77:2590-2601.
69. Andrews SC, Robinson AK, Rodriguez-Quinones F. Bacterial iron homeostasis. FEMS Microbiol Rev. 2003;27:215-237.
70. Seo SW, Kim D, Latif H, et al. Deciphering fur transcriptional regulatory network highlights its complex role beyond iron metabolism in Escherichia coli. Nat Commun. 2014;5:4910.
71. Davenport M, Poles J, Leung JM, et al. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:723-731.
72. Rooks MG, Veiga P, Wardwell-Scott LH, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 2014;8:1403-1417.
73. Schumann S, Alpert C, Engst W, et al. Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal escherichia coli strains in a gnotobiotic mouse model. Appl Environ Microbiol. 2012;78:1513-1522.
74. Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic escherichia coli strain Nissle 1917. J Bacteriol. 2004;186:5432-5441.
75. Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis. 2008;14:1597-1605.
76. Bailey JR, Probert CSJ, Cogan TA. Identification and characterisation of an iron-responsive candidate probiotic. PLoS One. 2011;6:e26507.
77. Grabig A, Paclik D, Guzy C, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74:4075-4082.
78. Joan ES, Owen MG, David CQ. Kin discrimination and cooperation in microbes. Annu Rev Microbiol. 2011;65:349-367.
79. Sassone-Corsi M, Nuccio S-P, Liu H, et al. Microcins mediate competition among enterobacteriaceae in the inflamed gut. Nature. 2016;540: 280-283.
80. Rebuffat S. Microcins in action: Amazing defence strategies of Enterobacteria. Biochem Soc Trans. 2012;40:1456-1462.
81. Lin CS, Tsai YH, Chang CJ, et al. An iron detection system determines bacterial swarming initiation and biofilm formation. Sci Rep. 2016;6:36747.
82. Scaldaferri F, Gerardi V, Mangiola F, et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J Gastroenterol. 2016;22: 5505-5511.
83. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2007;2:e1308.
84. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007;9:804-816.